Macogenic G2 for extracorporeal photopheresis

 

Photopheresis

Extracorporeal Photopheresis (ECP) has been recognised by the scientific community as a therapeutic option to treat various disorders, such as:

. Cutaneous T-cell lymphoma (Sezary syndrome)

. GVHD (acute and chronic)

. Solid organ transplant rejection

Macopharma has developed a complete product range for the off-line extracorporeal photpheresis technique.

Roue Photopheresis

DISCOVER PHOTOPHERESIS BROCHURE (UK)

DISCOVER PHOTOPHERESIS BROCHURE (FR)

Extracorporeal photopheresis (ECP) is based on the exposure of peripheral blood mononuclear cells to the photosensitizing agent (8-methoxypsoralen or 8-MOP) and UVA irradiation.
Mononuclear cells are harvested by an apheresis device usually and reinfused to the patient after cell irradiation.

Ref. XUV8501Q - Bag for U.V. treatment of blood cellsXUV8501Q

Download brochure for product description

Ref. CSL1800XA - Methoxsalen (8-MOP) MACO PHARMA 20 micrograms/mL, solution

Produit Thérapeutique Annexe (PTA)
Marketing Authorisation in France
AMM PTA N°: TA 07.10.109CSL1800XA

  • Volume: 5 mL

Download brochure for product description

Ref. 9MG2000 - Macogenic G2 9MG2000

  • Weight: 67 kg
  • Dimensions: 87 cm (width) x 64 cm (depth) x 38 cm (height)

Download brochure for product description